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Abstract 
Purpose: To investigate the role of chloroquine (CQ) in lipopolysaccharide (LPS)-induced renal injury in 
rats. 
Methods: Rats were assigned to one of four groups (n = 10). Control group was only given saline 
solution, whereas the model control, LPS + CQ, and LPS + yohimbine (YOH) + CQ groups were 
administered LPS intraperitoneally. At the end of the study, blood urea nitrogen (BUN) and creatinine 
(Cr) levels were determined. 
Results: CQ treatment significantly decreased the blood concentrations of tissue necrosis factor alpha 
(TNF-α), interleukin-6 (IL-6), IL-18, BUN, and Cr in the model control rats. There were also significant 
decreases in the levels of high mobility group protein 1 and kidney injury molecule-1 in the renal injury 
rats compared to the model control group. However, the inhibitory effects of CQ in the LPS-treated rats 
were blocked by treatment with YOH, an α-2-adrenergic receptor antagonist. 
Conclusions: Treatment with CQ attenuates LPS-induced renal injury by inhibiting inflammatory 
response. 
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Various factors can trigger a systemic 
inflammatory response, which is characterized by 
a reduction in oxygen uptake and myocardial 
contractility such as pathogen administration, 
trauma, hypoxia, reperfusion injury, and 
postoperative sepsis [1]. Sepsis has a mortality 
rate of 40 – 80 % and most commonly targets the 
kidneys [2]. Acute kidney injury (AKI) induced by 
sepsis has a 70 % mortality rate [3,4]. Factors 
related to the onset of inflammation include 
tissue necrosis factor alpha (TNF-α), interleukin-
6 (IL-6), and IL-18, which are expressed at 
higher concentrations under pathological 
conditions. Of these, IL-18 is a biomarker of AKI 
[5]. Injuries to organs are induced by the IL-18-
mediated expression of TNF-α and IL-6, which 
initiate an inflammatory reaction [6]. It is believed 
that inhibiting this inflammatory reaction is a 
promising strategy for preventing organ injury. 
 
Chloroquine (CQ, Figure 1) and its analogs 
exhibit a wide spectrum of biological activities 
including anti-cancer [7] and anti-hepatitis C virus 
[8,9] effects. CQ also readily crosses the blood-
brain barrier [10]. In addition, CQ analogs such 
as hydroxychloroquine have shown promise for 
the treatment of systemic lupus erythematosus 
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[11] and rheumatoid arthritis [12]. Experiments 
using a number of CQ analogs in a human 
diploid embryonic lung cell line (MRC-5) revealed 
their potential biological properties and lack of 
cytotoxic effects [13]. Therefore, this study 











Male 18-week-old Sprague–Dawley rats were 
obtained from Beijing Vital River Experimental 
Animal Technology (Beijing, China). The study 
was performed according to the European 
guidelines for animal use [14]. Study approval 
was obtained from the animal research ethics 
committee of The Provincial Hospital Affiliated 





CQ was dissolved in dimethyl sulfoxide and 
stored at -20 °C. Yohimbine (YOH) was obtained 




The rats were separated into four groups: 
untreated normal control group, model control 
group that was administered LPS 
intraperitoneally (i.p.), LPS + CQ treatment group 
that was treated with CQ after LPS 
administration, and LPS + YOH + CQ treatment 
group that was pretreated with YOH followed by 
CQ treatment after LPS administration. LPS, CQ, 
and YOH were administered at doses of 4, 5, 
and 1 mg/kg body weight, respectively after 12 h. 
 
Kidney damage analysis 
 
The rats were sacrificed by pentobarbital 
overdose (70 mg/kg, i.p.) after 12 h and the 
blood Cr, BUN, IL-6, IL-18, and TNF-α levels 
were determined using blood collected from the 
abdominal artery. An automated biochemistry 
analyzer (Hitachi 7600-020/7170A; Hitachi High-
Technologies, Tokyo, Japan) was used to 
measure the Cr and BUN levels. Immediately 
after sacrifice, the left kidney was isolated from 
all of the rats under liquid nitrogen, fixed in 
formalin, and stored at -78 °C. In addition, two 
biomarker molecules, high mobility group protein 
1 (HMGB-1) and kidney injury molecule-1 (KIM-
1), were measured in the renal tissue sections. 
To examine renal histology, renal tissues were 
fixed in formalin, embedded in paraffin, and 
examined under a microscope at 400 × 
magnification after hematoxylin and eosin 
staining. 
 
Measuring TNF-Α, IL-6, and IL-18 levels 
in the rat plasma 
 
To determine the TNF-α, IL-18, and IL-6 levels in 
the rat plasma, blood samples were taken from 
the rats and centrifuged at 12000 × g for 10 min. 
Then the serum was isolated and stored at -78 
°C. IL-6, IL-18, and TNF-α concentrations were 
measured using ELISA kits (Nanjing KeyGen 
Biotech, Jiangsu, China). 
 
Western blot analysis 
 
The renal tissue samples were washed twice 
with phosphate-buffered saline (PBS) and 
subsequently lysed in lysis buffer containing Tris-
HCl pH 7.4 (50 µM), sodium chloride (137 µM), 
10 % glycerol, 100 µM Na2 (VO3), 1 µM PMSF, 
aprotinin (10 mg/mL), leupeptin (10 mg/mL), 1 % 
NP-40, and cocktail (5 µM). The bicinchoninic 
acid assay was used to determine the protein 
concentration. The protein samples were loaded 
on 10 % polyacrylamide gels, resolved by 
electrophoresis, and electro transferred to poly 
(vinylidene fluoride) membranes using the semi-
dry method. The membranes were washed with 
Tris-buffered saline Tween (TBST) and blocked 
in 5 % non-fat dry milk for 12 h. Subsequently, 
the membranes were incubated overnight with 
primary antibodies against KIM-1 and HMGB-1 
(both purchased from Santa Cruz Biotechnology, 
Dallas, TX, USA), washed again with TBST, and 
incubated with secondary antibodies for 2 h. A 
chemiluminescent detection system was used to 
detect the protein bands, which were quantified 
using the Quantity One software package (Bio-
Rad, Hercules, CA, USA) using GAPDH (Thermo 





All of the experiments were conducted three 
times and the results are reported as the mean ± 
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SD. The results were compared using the 
Student’s t-test and p < 0.05 was considered 
statistically significant. SPSS software version 




Effects of CQ on BUN and creatinine 
levels in rats with LPS-induced AKI 
 
The BUN and creatinine (Cr) levels were 
markedly higher in the LPS-treated group than in 
the controls (Figure 2), and CQ treatment caused 
significant decreases in serum BUN and Cr 
levels in the LPS-induced sepsis rat model. 
However, the decrease in Cr and BUN caused by 
CQ was inhibited in rats pretreated with the α-2-
adrenergic receptor antagonist YOH, and Cr and 
BUN levels were similar to those of rats injected 
with LPS. 
 
The renal histology micrographs of LPS-treated 
and untreated control groups showed luminal 
swelling and flattened glomerular and renal 
tubule cells in LPS-treated rats. LPS treatment 
also induced degeneration of the tubular 
epithelium, the appearance of small tubular 
structures, and an inflammatory cell infiltrate. 
However, CQ treatment inhibited these changes, 
and the findings were similar to those of the non-
LPS control group. Pretreating rats with YOH 
followed by CQ treatment prevented the effects 
of CQ treatment (Figure 3). 
 
 
Figure 2: Effects of CQ and YOH on Cr and BUN levels in rats with LPS-induced renal injury. CQ treatment 
caused a significant decrease in serum levels of Cr and BUN in the LPS-induced kidney injury rat model 
 
 
Figure 3: Effects of CQ and YOH on renal histology in LPS-induced renal injury in rats. The changes in kidney 
tissue histopathology were examined with hematoxylin and eosin staining. CQ, chloroquine; YOH, yohimbine; 
LPS, lipopolysaccharide; magnification 200× 
Zhang et al 
Trop J Pharm Res, September 2017; 16(9): 2152  
 
Effects of CQ on HMGB-1 and KIM-1 
expression in the kidneys of LPS-treated 
rats 
 
The analysis of KIM-1 and HMGB-1, biomarkers 
of kidney damage, revealed significantly greater 
expression in rats treated with LPS (Figure 4). 
However, CQ treatment resulted in marked 
decreases in KIM-1 and HMGB-1 expression in 
LPS-treated rats. Treatment of rats given LPS 
with YOH followed by CQ prevented the CQ-
mediated decreases in KIM-1 and HMGB-1. 
Effects of CQ on the inflammatory 
reaction in the kidney 
 
There was increased expression of the 
inflammatory factors IL-6, IL-18, and TNF-α in 
the LPS-treated rats (Figure 5). CQ treatment 
induced a marked decrease in the expression of 
all three inflammatory factors, whereas 








Figure 5: Effects of CQ and YOH on TNF-α, IL-18, and IL-6 expression in rats with LPS-induced renal injury. IL, 
interleukin; TNF-α, tumor necrosis factor-α; YOH, yohimbine; LPS, lipopolysaccharide 
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Renal tubule injury is the cause of renal failure in 
more than 80 % of affected patients [15, 16]. This 
study demonstrated the effects of CQ on AKI in 
rats administered LPS. CQ treatment inhibited 
the effects of LPS and prevented renal damage, 
as evidenced by the decrease in KIM-1 and 
HMGB-1 expression. Pre-treatment of LPS-
treated animals with YOH blocked the effects of 
CQ, suggesting that CQ elicits its effects via the 
α-2 adrenoceptor. HMGB-1 binds to 
inflammatory mediators and induces the release 
of pro-inflammatory cytokines [17]. KIM-1, a 
transmembrane tubular protein, is expressed in 
the kidneys after renal injury and serves as a 
marker of renal injury [17]. Kidney injury involves 
an inflammatory reaction [18]. The reduction in 
the expression of factors responsible for 
inflammatory reactions caused by CQ, which was 
enhanced by LPS treatment, demonstrated the 
inhibitory effects of CQ on IL-6, IL-18, and TNF-α 
expression. The inflammatory reactions 
promoted by TNF-α and IL-6 factors are induced 
by IL-18 and cause organ injury [19]. 
 
This study showed that CQ treatment in LPS-
treated rats inhibited kidney injury via the 
suppression of factors involved in inflammation 
such as IL-6, IL-18, and TNF-α. However, 
pretreatment with the α-2-adrenergic receptor 
antagonist YOH blocked the effects of CQ in the 





The nephroprotective effects of CQ in LPS-
induced renal injury can be attributed to the 
inhibition of the inflammatory response. CQ may 
play a role in the management renal injury but 
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